Results 211 to 220 of about 210,637 (269)

Shorter ovarian stimulation is detrimental to fresh embryo transfer outcomes in PCOS women undergoing GnRH antagonist protocol: a retrospective cohort study. [PDF]

Sci Rep
Xiao S, Liu S, Hong L, Liu Z, Jia R, Zhang H, Mo M, Yang T.   +7 more
europepmc   +1 more source

Relationship Between Estradiol Levels Measured on the Initiation Day of GnRH Antagonist Treatment and Pregnancy Outcomes in Patients Receiving the Antagonist Protocol. [PDF]

Medicina (Kaunas)
Karaçin P, Özelçi R, Kumcu E, Kaya Kaplanoğlu D, Dilbaz S, Üstün Y.   +5 more
europepmc   +1 more source

Impact of GnRH antagonist pretreatment on oocyte yield after ovarian stimulation: A retrospective analysis. [PDF]

PLoS One
Federica DG, De Rijdt S, Racca A, Drakopoulos P, Mackens S, Strypstein L, Tournaye H, De Vos M, Blockeel C.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists.

Human Reproduction, 2000
When gonadotrophin-releasing hormone (GnRH) was discovered, the agonist and antagonist of GnRH were developed to control the release of FSH and LH by the gonadotrophs. More than 10 years of research were needed to develop a GnRH antagonist free of histamine release.
E R Hernández
exaly   +2 more sources

Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.

Human Reproduction, 2001
The gonadotrophin-releasing hormone (GnRH) antagonists, cetrorelix and ganirelix, have both been approved for ovarian stimulation to prevent a premature LH surge. Since GnRH receptors and their gene expression have been detected in human ovary, concern has risen over whether GnRH antagonists might affect ovarian function.
J M Weiss
exaly   +2 more sources

Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor.

Human Reproduction, 2000
Recent suggestions that gonadotrophin-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the studies cited in support of this suggestion are in-vitro studies, testing supra-pharmacological doses of GnRH analogues in cancer cell lines, whereas GnRH antagonists, e.g.
Bernadette Mannaerts, Keith Gordon
exaly   +2 more sources

GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate

Reproductive BioMedicine Online, 2013
The availability of gonadotrophin-releasing hormone (GnRH) antagonists for ovarian stimulation protocols has generated many meta-analyses comparing it to GnRH agonist long protocols. These meta-analyses have yielded conflicting results for pregnancy rate,
Raoul Orvieto, Pasquale Patrizio
exaly   +2 more sources

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Fertility and Sterility, 2005
Objective: To compare the efficacy of flare-up and GnRH-antagonist treatment in poor-responder patients. Design: Randomized prospective study. Setting: Assisted reproduction center.
Antonio La Marca, Daniela Tagliasacchi, Annibale Volpe   +2 more
exaly   +2 more sources

Applications for GnRH antagonists

Trends in Endocrinology and Metabolism, 2001
Abstract Meeting on the Potential Clinical Applications for Gonadotropin-Releasing Hormone Antagonists was held at the National Institutes of Health in Bethesda, MD, USA on 31 January 2001.
openaire   +2 more sources

GnRH-antagonists in reproductive medicine

Archives of Gynecology and Obstetrics, 2005
Suppression of sex steroid production based on desensitisation and down-regulation of pituitary gonadotropin-releasing hormone (GnRH)-receptors by agonistic GnRH-analogues resulting in the blockage of gonadotropin release from the anterior pituitary gland is a well-established approach in a variety of clinical conditions. Antagonistic analogues of GnRH
Georg, Griesinger, Ricardo, Felberbaum, Klaus, Diedrich   +2 more
openaire   +2 more sources